CSA Medical, Inc. — SEC Form D Filing
CSA Medical, Inc. filed an SEC Form D on July 23, 2026, reporting $2.91M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- July 23, 2026
- Amount reported
- $2.91M
- Industry
- Medical Devices
- Website
- https://rejuvenair.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: MARYLAND
Problem
Many Americans suffer from Chronic Bronchitis, a severe form of COPD characterized by a persistent cough, breathlessness, and wheezing. Existing treatments only offer symptomatic relief and do not target the underlying cause of the disease, leading to a significant decline in patients' quality of life.
Solution
The RejuvenAir System is a cryosurgical device that delivers liquid nitrogen to targeted areas in the lungs through a minimally invasive bronchoscopic procedure. This 'metered cryospray' destroys diseased cells while preserving the extracellular structure, allowing healthy cells to repopulate and thereby treating the underlying cause of COPD with Chronic Bronchitis.
Verdict
This cleared because it brought a novel ablation modality to an underserved, symptomatic, high-comorbidity patient population, not because it promised a transformative cure for a vast market. Investors were implicitly betting on a regulatory pathway that valued symptomatic improvement in a difficult-to-treat segment, recognizing the limited alternatives. Upside was likely capped by the niche application and the hurdle of physician adoption for a new, bronchoscopic-delivered device, rather than a broad market disruption.
Source: SEC EDGAR Form D filing